how much can you lose with semaglutide weight loss dosage chart How Long Do You Stay

The clinical differences are real but modest

Longer term, competition is likely to intensify beyond Lilly and compounders, as several drugmakers including Pfizer, Amgen, AstraZeneca, Roche advance late-stage candidates through their pipelines

[171] A 2025 observational study reported a modest increased risk of a serious eye condition in people with diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists

Cagrilintide is a next-generation investigational peptide that functions as a long-acting amylin receptor agonist

Generally, long-term data (like 2-3 years out) from trials show maintained improvements in weight and health markers with no new safety concerns